Massachusetts-based drug developer Sarepta Therapeutics has acquired private biotech Myonexus Therapeutics for $165m, after the publication of promising early data on a gene therapy clinical trial. Myonexus is testing the use of MYO-101 in patients with beta-sarcoglycanopathy, a severe form of limb-girdle muscular dystrophy (LGMD). Early results from three patients demonstrated MYO-101 prompted an average increase of 90% in beta-sarcoglycan, a protein needed for muscle function, which LGMD sufferers lack.
Massachusetts-based drug developer Sarepta Therapeutics has acquired private biotech Myonexus Therapeutics for $165m, after the publication of promising early data on a gene therapy clinical trial. Myonexus is testing the use of MYO-101 in patients with beta-sarcoglycanopathy, a severe form of limb-girdle muscular dystrophy (LGMD). Early results from three patients demonstrated MYO-101 prompted an average increase of 51% in beta-sarcoglycan, a protein needed for muscle function, which LGMD sufferers lack.